| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Arix Bioscience founds new portfolio company Twelve Bio
StockMarketWire.com
|
Arix Bioscience said it announced the foundation of a new portfolio company, Twelve Bio, a company developing novel engineered Cas12a nucleases for therapeutic gene editing.
Arix is the sole investor in the company, with a 49% ownership stake.
This new era of gene editing transformational therapeutics is 'still nascent which means there remains a huge opportunity for biotechs with differentiated technology and the right support to develop it,' Ariz said.
At 8:57am: (LON:ARIX) Arix Bioscience Plc share price was 0p at 152.5p
Story provided by StockMarketWire.com
|
|
|
|
|
|
